AlphAIAlphAI — Financial news for AI agents
investing.com$PAHC

Phibro Animal Health earnings beat by $0.02, revenue topped estimates

Phibro Animal Health (PAHC) reported Q1 EPS of $0.79, beating estimates by $0.02, with revenue at $386.6M, exceeding expectations. The company forecasts FY 2027 EPS of $3.41-$3.59 and revenue of $1.55B-$1.60B. Its stock is up 14.99% over 3 months but down 4.18% year-over-year.

Original reporting
investing.com
Published Nov 4, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PAHC
Bullish
high confidence
Mentioned
$PAHC
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PAHCBullishMed
01

Why it matters

The earnings surprise may trigger short covering and buying interest, but the modest magnitude suggests limited rally.

02

Market read

Primary earnings disclosure for a small‑cap biotech; relevant for traders focused on earnings surprises.

03

What to watch

Potential headwinds from commodity costs and competitive pricing could temper gains.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Phibro Animal Health reported Q1 results with a slight earnings beat and modest revenue beat, followed by FY2027 guidance marginally above consensus.

Company-level read

Ticker impact

$PAHCBullishHigh confidence
Context

Q1 EPS of $0.79 beat estimate by $0.02 and revenue of $386.6M topped consensus, with FY2027 guidance slightly above expectations.

Expected impact

likely upward as investors price in the earnings beat and higher guidance

Evidence & confidence

The beat and guidance are fresh primary data; markets typically reward such surprises.

Market effects

Sector

Animal health sector may see modest uplift as a peer demonstrates pricing power.

Regional

US small‑cap investors may rotate into PAHC on the beat.

Global

Limited; impact confined to niche animal health space.

Counterpoint

What could challenge this read

The beat is marginal; valuation may already reflect expectations, limiting upside.

Key entities

  • Company
    Phibro Animal Health

    NASDAQ‑listed animal health products manufacturer.

Read at source← All news

StoryPhibro Animal Health posts Q1 earnings beat and maintains FY2027 guidance

Also covered by

1 outlet

Related articles

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

finance.yahoo.com
$PAHCHighAI 8/10

Phibro Animal Health Corp (PAHC) (Q1 2027) Earnings Call Highlights: Solid Start to Fiscal

Phibro Animal Health (PAHC) reported Q1 2027 sales of $386.8M (+6%) and adjusted EBITDA of $64.3M (+4%). CEO Donnie Bantine expects Brazil Virginiamycin approval but no sales assumed in 2027. Zoetis portfolio drove MFA growth, while livestock margins are squeezed. USDA's border reopening impacts cattle imports. Net income rose 11% to $29.5M. Guidance remains unchanged, with net sales expected between $1.55B-$1.6B.

finance.yahoo.com
$PAHCMed

What Phibro Animal Health (PAHC) Said on Its Q1 Earnings Call

Phibro Animal Health (PAHC) reported Q1 adjusted EBITDA fell $1M due to higher SG&A expenses, despite increased gross profit. Mineral Nutrition and Performance Products sales rose 17% and 16%, respectively, with EBITDA gains. Companywide operating income declined $1.6M. Phibro maintained fiscal 2027 guidance, with net sales expected between $1.55B and $1.6B. Brazilian regulatory discussions continue, with no sales included in the forecast. Free cash flow was $22M over the past year.

finance.yahoo.com
$PAHCHighAI 8/10

Phibro Animal Health (NASDAQ:PAHC) exceeds Q3 CY2026 expectations

Phibro Animal Health (PAHC) reported Q3 CY2026 revenue of $386.8M, beating estimates by 3% and growing 6.3% year-on-year. Adjusted EPS met expectations at $0.79. Adjusted EBITDA rose 3.9% to $64.3M. The company reconfirmed its full-year revenue guidance of $1.58B and adjusted EPS guidance of $3.50, with EBITDA guidance of $263M, above analyst estimates.

finance.yahoo.com
$PAHCMed

Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ For Immediate Release ​ Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance ​ TEANECK, N.J., November 4, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced

SEC EDGAR 8-K
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com